ALK and non-small cell lung carcinoma: In this initial proof-of-concept effort, we confirmed robust performance of the LungFusion assay with 240 FFPE clinical samples obtained from advanced NSCLC patients, revealing a prevalence of 2.5%, 2.1%, and 0.4% for ALK, ROS1, and RET fusion genes, respectively.